Appili Therapeutics Inc. (APLIF)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 827.4 Thousand CAD | -96.68% |
| 2023 | 24.94 Million CAD | 73.59% |
| 2022 | 14.37 Million CAD | -11.72% |
| 2021 | 16.28 Million CAD | 272.35% |
| 2020 | 4.37 Million CAD | -38.8% |
| 2019 | 7.14 Million CAD | 89.63% |
| 2018 | 3.76 Million CAD | 0.23% |
| 2017 | 3.75 Million CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 1.17 Million CAD | -41.54% |
| 2024 FY | 8.83 Million CAD | -64.58% |
| 2024 Q3 | 2.39 Million CAD | 103.94% |
| 2024 Q4 | 2.42 Million CAD | 1.28% |
| 2024 Q1 | 2 Million CAD | -8.21% |
| 2023 Q1 | 2 Million CAD | -8.21% |
| 2023 Q4 | 2.18 Million CAD | -7.92% |
| 2023 FY | 24.94 Million CAD | 73.59% |
| 2023 Q3 | 2.37 Million CAD | 102.41% |
| 2023 Q2 | 1.17 Million CAD | -41.54% |
| 2022 Q2 | 11.05 Million CAD | 50.57% |
| 2022 FY | 14.37 Million CAD | -11.72% |
| 2022 Q4 | 2.18 Million CAD | -50.48% |
| 2022 Q3 | 4.41 Million CAD | -60.01% |
| 2022 Q1 | 7.33 Million CAD | 47.74% |
| 2021 FY | 16.28 Million CAD | 272.35% |
| 2021 Q3 | 4.27 Million CAD | 70.01% |
| 2021 Q1 | 2.59 Million CAD | 106.36% |
| 2021 Q2 | 2.51 Million CAD | -3.34% |
| 2021 Q4 | 4.96 Million CAD | 16.32% |
| 2020 FY | 4.37 Million CAD | -38.8% |
| 2020 Q4 | 1.25 Million CAD | -6.36% |
| 2020 Q3 | 1.34 Million CAD | 20.88% |
| 2020 Q2 | 1.11 Million CAD | -41.01% |
| 2020 Q1 | 1.88 Million CAD | 51.85% |
| 2019 Q1 | 680.26 Thousand CAD | -43.93% |
| 2019 FY | 7.14 Million CAD | 89.63% |
| 2019 Q2 | 1.29 Million CAD | 91.02% |
| 2019 Q3 | 1.15 Million CAD | -11.46% |
| 2019 Q4 | 1.24 Million CAD | 7.97% |
| 2018 FY | 3.76 Million CAD | 0.23% |
| 2018 Q4 | 1.21 Million CAD | 18.34% |
| 2018 Q3 | 1.02 Million CAD | 0.0% |
| 2017 FY | 3.75 Million CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 99.047% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 83.176% |
| SQZ Biotechnologies Company | 85.61 Million USD | 99.034% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 97.2% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 97.779% |
| Mesoblast Limited | 5.9 Million USD | 85.981% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 44.909% |
| Genus plc | 147.7 Million USD | 99.44% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 90.575% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 38.324% |
| Marizyme, Inc. | 19.23 Million USD | 95.7% |
| ContraFect Corporation | 56.88 Million USD | 98.546% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 90.078% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 81.232% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 44.047% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 71.628% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 70.348% |
| MultiCell Technologies, Inc. | 567.42 USD | -145719.146% |
| Accustem Sciences Inc. | 3.74 Million USD | 77.915% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 99.037% |
| EV Biologics, Inc. | 531.96 Thousand USD | -55.539% |
| Q BioMed Inc. | 3.43 Million USD | 75.924% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 96.652% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -112.392% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 68.51% |
| Biomind Labs Inc. | 994.18 Thousand USD | 16.775% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 99.633% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 87.684% |
| Skye Bioscience, Inc. | 13.54 Million USD | 93.893% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 59.613% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 3409.628% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 83.59% |
| IMV Inc. | 37.7 Million USD | 97.806% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 94.832% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 54.912% |
| GB Sciences, Inc. | 1.42 Million USD | 41.753% |
| Alpha Cognition Inc. | 9.7 Million USD | 91.475% |
| HST Global, Inc. | 140.9 Thousand USD | -487.201% |
| CSL Limited | 3.44 Billion USD | 99.976% |
| Halberd Corporation | 74.84 Thousand USD | -1005.538% |
| Enzolytics Inc. | 2.17 Million USD | 62.037% |
| Resverlogix Corp. | 12.71 Million USD | 93.491% |
| Affymax, Inc. | 39.38 Million USD | 97.899% |
| SYBLEU INC | 160.87 Thousand USD | -414.314% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 77.336% |
| argenx SE | 1.53 Billion USD | 99.946% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 98.56% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 20.746% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 47.611% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 75.7% |
| AVAX Technologies, Inc. | 7.31 Million USD | 88.682% |
| Zenith Capital Corp. | 8.94 Million USD | 90.748% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.9% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -4649.481% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 66.301% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -382.428% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.167% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 52.98% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 1.97 Million USD | 58.043% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 55.62% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 92.386% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 56.926% |
| BioStem Technologies, Inc. | 22.97 Million USD | 96.399% |
| ONE Bio Corp. | 6.44 Million USD | 87.16% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -355.909% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | 38.042% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 26.447% |
| Agentix Corp. | 1.37 Million USD | 39.683% |
| LadRx Corporation | 3.81 Million USD | 78.293% |
| Cell Source, Inc. | 4.32 Million USD | 80.871% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -99.145% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 10.406% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 10.406% |
| NovAccess Global Inc. | 2.46 Million USD | 66.458% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 65.595% |
| Itoco Inc. | 919.14 Thousand USD | 9.981% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 80.478% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 26.058% |
| Kadimastem Ltd | 2.41 Million USD | 65.669% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -216.135% |
| CytoDyn Inc. | 18.05 Million USD | 95.418% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -3187.405% |
| Mobile Lads Corp. | 554.54 Thousand USD | -49.204% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -275.961% |
| Qrons Inc. | 643.67 Thousand USD | -28.544% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 41.723% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | 62.895% |
| Rebus Holdings, Inc. | 664 Thousand USD | -24.609% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 54.446% |
| International Stem Cell Corporation | 5.27 Million USD | 84.303% |
| Bioxytran, Inc. | 3.82 Million USD | 78.341% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -1471.762% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -3967.281% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 97.719% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 48.862% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -12.445% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 73.404% |
| Neutra Corp. | 243.82 Thousand USD | -239.35% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 95.26% |
| PureTech Health plc | 144.59 Million USD | 99.428% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 95.962% |
| IXICO plc | 4.7 Million USD | 82.422% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 90.594% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.297% |
| CSL Limited | 3.89 Billion USD | 99.979% |
| Cellectis S.A. | 97.32 Million USD | 99.15% |